8-K: Tivic Health Secures $25M Equity Line and Reports Year-End 2024 Financial Results Amid Strategic Shift

Tivic Health Systems, Inc. announces a $25M equity purchase agreement, year-end 2024 financial results, and highlights its strategic transformation into a diversified therapeutics company.

Summary

• Tivic Health Systems, Inc. has entered into an Equity Purchase Agreement with Mast Hill Fund, L.P., providing the company with access to up to $25 million over the next 24 months.
• Under the agreement, Tivic Health has the right, but not the obligation, to sell shares of its common stock to the investor, with the investor obligated to purchase them, subject to certain conditions.
• The purchase price for the shares will be 95% of the lowest VWAP of the company's common stock over a 5-day pricing period after the investor receives the shares.
• The company issued 29,800 restricted shares of common stock to the investor as consideration for their commitment.
• Craft Capital Management LLC acted as the company's placement agent for the transaction and will receive a 3.0% commission on the gross proceeds from each sale of shares.
• Tivic Health also reported its year-end 2024 financial results, with revenue totaling $0.8 million, a decrease from $1.2 million in 2023.
• The company's net loss for 2024 was $5.7 million, an improvement from the $8.2 million loss in 2023.
• Cash and equivalents at the end of 2024 totaled $2.0 million.
• The company is focusing on advancing its non-invasive cervical vagus nerve stimulation (ncVNS) devices and its newly licensed TLR5 agonist assets.
• Tivic Health has secured access to a $25M equity line of credit to support the company's advance research programs, which, if fully utilized, would fully fund commercialization of Entolimod.

Sentiment

Score: 6

Explanation: While the company is strategically pivoting and securing funding, the financial results show a decline in revenue and cash, balancing positive developments with concerning financial metrics.

Positives

• The $25 million equity line provides Tivic Health with additional financial flexibility.
• The company decreased its year-over-year net loss by 30 percent.
• Tivic Health is expanding its pipeline with both device and drug candidates.
• The company is advancing its ncVNS device program and its TLR5 agonist assets.
• Tivic Health has 27 patents issued and pending, with additional licensed rights under more than 60 patents related to Entolimod and Entolasta.
• The company secured access to a $25M equity line of credit to support the company's advance research programs, which, if fully utilized, would fully fund commercialization of Entolimod.

Negatives

• Revenue decreased to $0.8 million for the year ended December 31, 2024, compared to $1.2 million for the year ended December 31, 2023.
• Gross profit for the year ended December 31, 2024 was $2,000 compared with $287,000 for the year ended December 31, 2023.
• Cash and equivalents decreased to $2.0 million at December 31, 2024, compared with $3.4 million at December 31, 2023.

Risks

• Actual sales of shares to the investor will depend on market conditions and the company's funding needs.
• The company may need to obtain stockholder approval to issue additional shares under Nasdaq rules.
• The company's future results are subject to risks and uncertainties, including those related to product development, regulatory approval, and market conditions.
• The company's ability to raise additional capital on favorable terms is uncertain.
• The company's ability to maintain its Nasdaq listing is uncertain.
• The company's ability to commercialize products arising out of its ncVNS program and TLR5 program is uncertain.

Future Outlook

Tivic Health plans to increase its research and development investments in its vagus nerve platform and clinical applications and to advance the development of Tivic's licensed TLR5 agonist programs.

Management Comments

• 'The important strategic events of the past several months have been nothing short of transformative,' stated Tivic Health Chief Executive Officer, Jennifer Ernst.
• 'We have successfully reshaped the company by expanding Tivics opportunities in the biotech sector by in-licensing a late-stage biologic immunotherapy and advancing our ongoing work on our next-generation non-invasive cervical vagus nerve stimulation (ncVNS) devices,' added Ernst.
• 'As we look further into 2025 and the evolution of the company, our confidence grows as we prepare to move into disease-specific clinical trials for ncVNS later this year,' concluded Ernst.

Industry Context

The company is positioning itself in the growing fields of bioelectronic medicine and immunotherapeutics, targeting conditions with significant unmet needs.

Comparison to Industry Standards

• The company's non-invasive vagus nerve stimulation (VNS) approach is differentiated from existing surgical implants, potentially offering broader applicability.
• The TLR5 agonist program, with Entolimod, targets acute radiation syndrome (ARS), a market with limited treatment options and potential for government stockpiling.
• The company's strategy of combining bioelectronic devices and biologic drugs creates a unique therapeutic pipeline.

Management Changes

Stakeholder Impact

• Shareholders may be impacted by the potential dilution from the issuance of shares under the Equity Purchase Agreement.
• Employees may be impacted by the company's strategic shift and focus on new programs.
• Patients may benefit from the development of new treatment options for neurologic, cardiac, autonomic-related diseases, and acute radiation syndrome.

Next Steps

• The company will file a registration statement covering the shares issuable under the Equity Purchase Agreement.
• Tivic Health expects to advance into disease-specific clinical trials for ncVNS later this year.
• The company will continue to develop its TLR5 agonist programs, specifically, Entolimod and Entolasta.

Key Dates

Keywords

Equity Purchase Agreement, Tivic Health, Mast Hill Fund, Common Stock, Financial Results, Registration Rights, Entolimod, ncVNS, TLR5 agonist, Shares